Poseida Therapeutics, Inc. Deferred Revenue Recognized
Poseida Therapeutics, Inc. reported Deferred Revenue Recognized of -$125.86 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2024-11-07
- Poseida Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was -$28.14M.
- Poseida Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was -$10.34M.
- Poseida Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was -$130.49M.
- Poseida Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was -$31.24M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$125.86M 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | -$54.12M 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | -$28.14M 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | -$64.70M 10-Q · filed 2024-11-07 | |||
| 2023-09-30 | -$39.71M 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | -$30.36M 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | -$10.34M 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | -$130.49M 10-K · filed 2024-03-07 | |||
| 2022-09-30 | -$120.44M 10-Q · filed 2022-11-10 | |||
| 2021-12-31 | -$31.24M 10-K · filed 2023-03-09 |